Severe eczematous skin reaction after high-dose intravenous immunoglobulin infusion: Report of 4 cases and review of the literature

Archives of Dermatology

Volumn 142, Issue 2, 2006, Pages 213-217

  Vecchietti, Gianluca ^a   Kerl, Katrin ^a   Prins, Christa ^a   Kaya, Gürkan ^a   Saurat, Jean Hilaire ^a   French, Lars E ^a,b  

^a UNIVERSITY OF GENEVA   (Switzerland)

^b GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BETAMETHASONE DIPROPIONATE; CLOMIPRAMINE; CLORAZEPATE DIPOTASSIUM; CORTICOSTEROID; GABAPENTIN; IMMUNOGLOBULIN; MESALAZINE; PREDNISONE; REDIMMUNE; STEROID;

ADULT; ARTICLE; CASE REPORT; DESQUAMATION; DISEASE COURSE; DISEASE SEVERITY; DRUG INFUSION; DRUG MEGADOSE; ECZEMA; FOOT SOLE; HAND PALM; HUMAN; LICHENOID ERUPTION; MACULOPAPULAR RASH; MALE; NEURITIS; PAPULOVESICULAR RASH; PATIENT; PRIORITY JOURNAL; RASH; SKIN BIOPSY; SKIN DEFECT; SKIN MANIFESTATION;

BIOPSY; DIAGNOSIS, DIFFERENTIAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ECZEMA; FOLLOW-UP STUDIES; GLUCOCORTICOIDS; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC FACTORS; MALE; MIDDLE AGED; POLYRADICULONEUROPATHY; SKIN;

EID: 33244467913     PISSN: 0003987X     EISSN: None     Source Type: Journal    
DOI: 10.1001/archderm.142.2.213     Document Type: Article

References (27)

1. Dwyer JM. Manipulating the immune system with immune globulin. N Engl J Med. 1992;326:107-116.
2. Kazatchkine MD, Kaveri SV. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med. 2001;345:747-755.
3. Sewell WA, Jolles S. Immunomodulatory action of intravenous immunoglobulin. Immunology. 2002;107:387-393.
4. Jolles S, Hughes J, Whittaker S. Dermatological uses of high-dose intravenous immunoglobulin. Arch Dermatol. 1998;134:80-86.
5. Newburger JW, Takahashi M, Beiser AS, et al. A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. N Engl J Med. 1991;324:1633-1639.
6. Viard I, Wehrli P, Bullani R, et al. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science. 1998;282:490-493.
7. Sekul EA, Cupler EJ, Dalakas MC. Aseptic meningitis associated with high-dose intravenous immunoglobulin therapy. Ann Intern Med. 1994;121:259-262.
8. Brox AG, Cournoyer D, Sternbach M, Spurll G. Hemolytic anemia following intravenous gamma globulin administration. Am J Med. 1987;82(3 spec No.):633-635.
9. Dalakas MC. High-dose intravenous immunoglobulin and serum viscosity: risk of precipitating thromboembolic events. Neurology. 1994;44:223-226.
10. Misbah SA, Chapel HM. Adverse effects of intravenous immunoglobulin. Drug Saf. 1993;9:254-262.
11. Tan E, Hajinazarian M, Bay W, Neff J, Mendell JR. Acute renal failure resulting from intravenous immunoglobulin therapy. Arch Neurol. 1993;50:137-139.
12. Chan-Lam D, Fitzsimons EJ, Douglas WS. Alopecia after immunoglobulin infusion. Lancet. 1987;1:1436.
13. Rodeghiero F, Castaman G, Vespignani M, Dini E, Bertazzoni M. Erythema multiforme after intravenous immunoglobulin. Blut. 1988;56:145.
14. Barucha C, McMillan JC. Eczema after intravenous infusion of immunoglobulin. Br Med J (Clin Res Ed). 1987;295:1141.
15. Hamdalla HH, Hawkes CH, Spokes EG, Bamford JM, Goulding PJ. Intravenous immunoglobulin in the Guillain-Barre syndrome. BMJ. 1996;313:1399-1400.
16. Sorensen PS, Wanscher B, Jensen CV, et al. Intravenous immunoglobulin G reduces MRI activity in relapsing multiple sclerosis. Neurology. 1998;50:1273-1281.
17. Whittam LR, Hay RJ, Hughes RA. Eczematous reactions to human immune globulin. Br J Dermatol. 1997;137:481-482.
18. Barbaud A, Trechot P, Granel F, et al. A baboon syndrome induced by intravenous human immunoglobulins. Dermatology. 1999;199:258-260.
19. Leclech C, Maillard H, Penisson-Besnier I, Laine-Cessac P, Verret JL. Unusual skin reaction after intravenous infusion of polyvalent immunoglobulins: 3 case reports [in French]. Presse Med. 1999;28:531.
20. Iannaccone S, Sferrazza B, Quattrini A, Smirne S, Ferini-Strambi L. Pompholyx (vesicular eczema) after IV immunoglobulin therapy for neurologic disease. Neurology. 1999;53:1154-1155.
21. Ikeda K, Iwasaki Y, Ichikawa Y, Kinoshita M. Pompholyx after IV immunoglobulin therapy for neurologic disease. Neurology. 2000;54:1879.
22. Uyttendaele H, Obadiah J, Grossman M. Dyshidrotic-like spongiotic dermatitis after intravenous immunoglobulin therapy. J Drugs Dermatol. 2003;2:337-341.
23. Tada M, Tada M, Ishiguro H, Yagi E, Hirota K. Eczematous reactions after intravenous immunoglobulin therapy in two patients with Guillain-Barre syndrome and a patient with Miller Fisher syndrome [in Japanese]. No To Shinkei. 2003;55:401-405.
24. Dalakas MC. The use of intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases. Pharmacol Ther. 2004;102:177-193.
25. Ruetter A, Luger TA. Efficacy and safety of intravenous immunoglobulin for immunemediated skin disease: current view. Am J Clin Dermatol. 2004;5:153-160.
26. Osei A, Uttenreuther-Fischer MM, Lerch H, Gaedicke G, Fischer P. Restricted VH3 gene usage in phage-displayed Fab that are selected by intravenous immunoglobulin. Arthritis Rheum. 2000;43:2722-2732.
27. Leucht S, Uttenreuther-Fischer MM, Gaedicke G, Fischer P. The B cell superantigenlike interaction of intravenous immunoglobin (IVIG) with Fab fragments of V(H) 3-23 and 3-30/3-30.5 germline gene origin cloned from a patient with Kawasaki disease is enhanced after IVIG therapy. Clin Immunol. 2001;99:18-29.